HBI-8000 has now entered into a Phase I clinical trial in the US under an IND application with the FDA.
HBI-8000 trial is designed to assess safety, tolerability and antitumor activity of HBI-8000 in patients with advanced solid tumors and lymphomas.
HUYA is planning for a US Phase II clinical trials and discussing partnerships with pharmaceutical companies interested in advancing the development and commercialisation of HBI-8000.
The drug has completed Phase I trials in China, in which it exhibited encouraging antitumor efficacy and a favorable toxicity profile, while the Phase II study is being conducted by Chipscreen Bioscience in China.
HUYA CEO Mireille Gingras said that the initiation of the Phase I trial for HBI-8000 in the US is a significant achievement for HUYA.
“It represents both an important development milestone for this promising cancer drug and illustrates the benefits of Chinese and Western biopharmaceutical companies working together to efficiently carry out drug development,” Gingras said.
Quintiles Capital group senior vice president Tom Perkins said that the agreement would help accelerate the development of medicines from China.
HUYA partners with Chinese research institutions and pharmaceutical companies to leverage and extend their research efforts, accelerate development, and provide a bridge to the US development process and worldwide pharmaceutical markets.
HUYA has licensed all ex-China rights to HBI-8000 from Chipscreen Bioscience.